Other languages Optimi Health Corp.

Equities

OPTI

CA68405H1001

Market Closed - Canadian Securities Exchange Other stock markets 15:59:59 2024-05-15 EDT			5-day change	1st Jan Change
0.36 ^CAD	0.00%		-5.26%	+46.94%

05-14	Optimi Health Receives Certificate of Analysis for Mdma 40Mg and 60Mg Gmp Capsules	CI
05-09	Optimi Health Corp. Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Optimi Health Receives Certificate of Analysis for Mdma 40Mg and 60Mg Gmp Capsules	05-14
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research	04-23
Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical Ingredient	04-15
Optimi Health Corp. Signs Psilocybin Supply Agreement with Matai Medical Research Institute	04-09
Optimi Health Corp. Receives Finished Product Test Results and Certificate of Analysis for GMP Natural Psilocybin Extract	04-02
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University	03-26
Optimi Health Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-29
Optimi Health Corp. Reports Earnings Results for the Full Year Ended September 30, 2023	01-28
Optimi Health Corp.: Optimi Health sichert sich ergänzende Zulassung zur Steigerung der Produktionsmengen von MDMA, MDA und 2C-B im Rahmen seiner Händlerlizenz für kontrollierte Arzneimittel und Substanzen	01-22
Sunshine Earth Labs Ltd. and Optimi Health Corp. Announce Strategic Supply Agreement	12-07
Optimi Health Corp. Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing	11-28
Optimi Health Corp. Announces Executive Changes	11-07
Optimi Health Corp. Announces Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial	23-09-14
Optimi Health Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-22
Optimi Health Corp. Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent	23-08-01
Optimi Health Corp. Announces Receipt of Purports Termination Notice	23-07-27
Optimi Health Corp. To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS	23-06-15
Optimi Health Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-24
Natural Health Grants Optimi Health Corp. Product Site License by Health Canada	23-05-10
Optimi Health Announces CAD 1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development	23-05-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Optimi Health Corp.

Equities

OPTI

CA68405H1001

Other languages

Filters